Oligonucleotide Therapeutics and Delivery 2022

Oligonucleotide Therapeutics and Delivery is organized by SAE Media Group (SMG) and will be held from Sep 21 - 22, 2022 at Copthorne Tara Hotel London Kensington, London, England, United Kingdom.

Description:
Advancements in extra-hepatic delivery of oligonucleotides

The emerging medicine class of Oligonucleotide Therapeutics is harnessing the therapeutic benefits of targeting genetic material using oligonucleotide conjugates, antisense, and oligonucleotides. Their potential to offer more effective and less toxic alternatives for small molecules, as well as the ability to target targets that were previously considered non-druggable, is driving their market growth. Even with recent technological advancements, efficient oligonucleotide distribution, especially to extrahepatic tissues remains a major translational limitation. This has created a market need for drug delivery technology investments.

The Oligonucleotide Therapeutics and Delivery conference will present the most recent in oligonucleotide delivery and discovery. It also includes presentations on targeted delivery mechanisms and oligonucleotide chemical chemistries, as well as clinical advancements. Global Experts from large pharma and top biotechs will discuss the new therapeutic applications of Oligonucleotides. They will also present case studies on the development and discovery of oligonucleotide therapeutics. This conference offers high-quality information and connections from the industry on the most recent clinical trial candidates. It also provides a platform to exchange ideas and help tackle the greatest challenge of all: Delivery.

We are proud to announce the launch of the Oligonucleotide Therapeutics series. We look forward to seeing you at Oligonucleotide Therapeutics & Delivery, where we will be discussing how to maximize the potential of oligo-based therapies.

Plus, two interactive half-day pre-conference workshops on the 20th of September 2022:
• Oligonucleotide Therapy - Overcoming the Challenges Of Delivery, led by Nick Lench Executive Director, NATA Martin Kerr Head of Business Development & Partnerships Nucleic Acid Therapy Accelerator Ritwick Sawakar, MRC Investigator and MRC Toxicology Unit University Of Cambridge
• Mia Kiistala (CEO/Principal Consultant at Aurora CMC Consulting) is responsible for managing CMC activities for the development of Oligonucleotide Therapeutics.

Chairs For 2022:
• Ekkehard Leberer, Senior Life Sciences Consultant, Elbicon
• Jimmy Weterings Principal Scientist, AstraZeneca

Benefits from Attending:
• Hear case studies that present clinical and preclinical research in oncology. What can we learn for future clinical trials?
• Increase your knowledge of the therapeutic delivery of oligonucleotides and learn about the latest innovations in delivery and targeting.
• Learn about the regulatory and CMC environment for oligonucleotide therapeutic developments
• Learn about the latest developments in oligonucleotide chemical chemistries, and look at developments in new applications of antisense Oligonucleotides.
• Get the most recent innovations in Oligonucleotide Therapeutics, such as using AI Machine Learning to discover new therapeutics

2022 Speakers
• Shalini Anderson, Vice President Oligonucleotide Discovery, AstraZeneca
• Heinrich Haas, Vice President RNA Formulation & Drug Delivery, BioNTech
• Tamar Grossman is the Global Head of RNA Targeted Therapeutics and RNA at Janssen Pharmaceuticals.
• Sarah Tabrizi Director of UCL Huntington's Disease Centre, UCL Institute of Neurology
• Macarena Hernandez-Jimenez, Chief Scientific Officer, AptaTargets
Sirnaomics Chief Scientific Officer David Evans
• Eric Lim, Director, Platform, Discover Research, Stoke Therapeutics, Inc.
• Chris Chorley Associate Director, Global Regulatory CMC Biogen
• Oliver Ernst, Managing Director, Chief Operating Officer, Neuway Pharma GmbH
• Nick Lench Executive Director, Nucleic Acid Therapy Accelerator
• Bart Anderson Senior Director of R&D at Exicure